Warning Letter Wednesday Posts
A weekly exploration of FDA warning letters and enforcement trends
Takeaway -
When will FDA go after “Nature’s Ozempic” claims
Takeaway -
Do not over-explain clinical research
Takeaway -
Blogs are “labeling”
Takeaway -
Disease claims trigger deeper FDA review
Takeaway -
Cosmetics are not "FDA-approved"
Takeaway -
Even lower risk statements can trigger NAD scrutiny
Takeaway -
Copackers & distributors must comply with GMPs
Takeaway -
Flu & virus claims are enough for regulatory action
Takeaway -
Specifications continue to be cited
Takeaway -
Unsafe products marketed to children are deceptive
Takeaway -
Food safety plans should be comprehensive
Takeaway -
Review of NAD case